Deadly Medicines and Organised Crime by Gotzsche Peter

Author:Gotzsche, Peter [Gotzsche, Peter]
Language: eng
Format: epub, mobi
ISBN: 9781908911124
Publisher: Radcliffe Publishing Ltd
Published: 2013-08-30T00:00:00+00:00

References

1 Vedantam S. Antidepressant makers withhold data on children. Washington Post. 2004 Jan 29.

2 Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326: 1171–3.

3 Melander H. [Selective reporting – greater problem than selective publishing?] Läkartidningen. 2005; 102: 224–5.

4 Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358: 252–60.

5 Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008; 5: e217.

6 Lenzer J. Drug secrets: what the FDA isn’t telling. Slate. 2005 Sept 27.

7 Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.

8 Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med. 2006; 99: 337–41.

9 Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev. 2007; 2: MR000005.

10 MacLean CH, Morton SC, Ofman JJ, et al. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol. 2003; 56: 44–51.

11 Goldacre B. Bad Pharma. London: Fourth Estate; 2012.

12 Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990; 263: 1405–8.

13 Danish Association of the Pharmaceutical Industry. [Revised collaborative agreement between the Medical Association and the Danish Association of the Pharmaceutical Industry about clinical trials and non-intervention studies]. 2010 June 1.

14 Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. BMJ. 2011; 342: d2686.

15 Wikipedia. Rimonabant. Available online at: http://en.wikipedia.org/wiki/Rimonabant (accessed 17 January 2013).

16 World Medical Association. Declaration of Helsinki – ethical principles for medical research involving human subjects. 2008.

17 Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 2011; 12: 249.

18 Topol EJ. Failing the public health – rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351: 1707–9.

19 Lenzer J. FDA is incapable of protecting US ‘against another Vioxx’. BMJ. 2004; 329: 1253.

20 Anonymous. Institute of Medicine urges reforms at FDA. Lancet. 2006; 368: 1211.

21 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.

22 Carpenter D. Drug-review deadlines and safety problems (authors’ reply). N Engl J Med. 2008; 359: 96–8.

23 Moore TJ. Deadly Medicine: why tens of thousands of heart patients died in America’s worst drug disaster. New York: Simon & Schuster; 1995.

24 Cowley AJ, Skene A, Stainer K, et al. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol. 1993; 40: 161–6.

25 EMA. European Medicines Agency Widens Public Access to Documents. Press release. 2010 Nov 30.

26 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents.

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.